Cue Biopharma (CUE) FCF Margin (2018 - 2025)

Cue Biopharma (CUE) posted FCF Margin of 11.33% for Q4 2025, up 97.3% sequentially from 419.92% in Q3 2025, and up 56164.0% YoY from N/an in Q4 2024.

Cue Biopharma (CUE) FCF Margin (2018 - 2025) Analysis & Trends

Cue Biopharma has reported FCF Margin for 8 years, with the latest figure at 11.33% in Q4 2025.

Quarterly FCF Margin rose 56164.0% year-over-year to 11.33% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 145.53% (up 24636.0% YoY) and the FY2025 annual result came in at 79.6%, up 31229.0% from the prior year.
FCF Margin advanced to 11.33% in Q4 2025 per CUE's latest filing, from 419.92% in the prior quarter.
Over five years, FCF Margin peaked at 11.33% in Q4 2025 and troughed at 49665.38% in Q2 2022.
A 5-year average of 4068.52% and a median of 573.0% in 2024 frame the typical range for FCF Margin.
The sharpest annual moves came in 2022 and 2023: FCF Margin sank 4929948 bps in 2022, then jumped 4891495 bps in 2023.
Over 5 years, FCF Margin stood at 128.96% in 2021, then slumped by 5300 bps to 6963.58% in 2022, then surged by 91 bps to 601.76% in 2023, then gained by 5 bps to 572.97% in 2024, then surged by 98 bps to 11.33% in 2025.
According to Business Quant data, FCF Margin over the past three periods registered 11.33%, 419.92%, and 116.52% for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	13.35%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	22.62%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	41.07%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-22.35%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	70.82%
10	Cue Biopharma	152.56 Mn	135.14 Mn	-	-

Download Data